OSRHOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

OSR Health, Inc.

OSR Health, Inc. is a U.S.-based healthcare company organized around medical device distribution through its subsidiary RMC. The company also has exposure to healthcare technology initiatives, including noninvasive glucose monitoring and other healthcare-related investments.

Revenue2.9m USD
Operating profit (EBIT)-18.3m USD
−420.2 %y/y
EBIT margin-631.0%
Net income-27.1m USD
−1,022.4 %y/y

Fiscal year 2025 · change from previous year

Development 2021–2025

-20-15-10-505m USD2021: EBIT -0.00 m USD20212022: EBIT -0.04 m USD20222023: EBIT -1.8 m USD20232024: EBIT -3.5 m USD20242025: 2.9 m USD2025: EBIT -18 m USD20252.9-18
RevenueOperating profit (EBIT)

Business

Share of revenue
Medical device distribution85 %

Distribution and resale of medical devices through the RMC subsidiary.

Commission revenue10 %

Commission-based revenue recognized under consignment-style supplier arrangements.

Healthcare technology development5 %

Development and commercialization efforts around noninvasive glucose monitoring.

Customers

The company sells primarily into healthcare channels that purchase medical devices for clinical use and resale. Its technology initiatives are aimed at diabetes care and broader healthcare technology markets, where buyers value less invasive monitoring and differentiated device performance.

Healthcare distributors and suppliers

Buy or supply medical devices through RMC's distribution network and consignment arrangements.

Hospitals and clinical end users

Purchase medical devices for direct patient care and operational use.

Diabetes technology market

Potential buyers and partners for noninvasive glucose monitoring solutions.

Healthcare investment partners

Provide capital or strategic support for healthcare technology initiatives.

Strategy

The company’s near-term strategy centers on stabilizing medical device economics through consignment-based supplier arrangements and improving the quality of gross profit. It is also pursuing healthcare technology opportunities, especially noninvasive glucose monitoring, to add a higher-growth platform alongside distribution operations.

Consignment-based distribution modelShort term

Reduces inventory risk and changes revenue recognition toward commission income.

Noninvasive CGM commercializationMedium term

Adds a differentiated technology platform in diabetes care with growth potential.

Healthcare technology portfolio expansionMedium term

Diversifies the business beyond device distribution and creates optionality.

Geography

OSR Health is headquartered in the United States, while a meaningful part of its operating and strategic activity is tied to South Korea through subsidiary and technology relationships. The company’s reported business also references cross-border healthcare investments and licensing, which makes its exposure more international than a typical U.S. device distributor.

Risks

The business depends on supplier relationships, product availability, and successful execution of contract changes, so disruptions can quickly affect revenue and margins. It also faces financing, dilution, and going-concern style risks typical of early-stage public healthcare companies with limited operating scale and ongoing capital needs.

Sorted by severity
Supplier concentration and contract dependenceHigh

A major portion of distribution economics depends on a limited number of supplier relationships.

Exposure: RMC medical device distribution

Revenue recognition volatility from consignment transitionHigh

Moving from purchase-resale to commission revenue changes timing and level of reported sales.

Exposure: Medical device distribution

Financing and dilution riskHigh

The company has relied on equity issuance, convertible bonds, loans, and ELOC funding.

Exposure: Corporate funding

Technology commercialization riskHigh

Noninvasive CGM requires clinical validation, regulatory clearance, and market adoption.

Exposure: Woori IO / CGM initiative

Public company compliance cost burdenMedium

Operating as a public company increases SG&A and administrative complexity.

Exposure: Corporate overhead

Accounting

Judgemental items
Revenue recognition under consignment arrangements

Only commission revenue is recognized, changing reported sales and margin presentation.

Impact: Affects net sales, gross profit, and comparability across periods

Inventory transition transactions

Selling inventory back to a supplier at cost temporarily depressed gross margin.

Impact: Can create quarter-to-quarter volatility in gross profit

Intangible asset amortization

Amortization is included in SG&A and can materially affect operating expense trends.

Impact: Reduces reported operating income

Equity financing and dilution instruments

ELOC, warrants, and convertible securities require careful equity and liability accounting.

Impact: Affects share count, capital structure, and financing costs

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026